Dabrafenib-Trametinib Combo Proves Active in Rare BRAF-Mutated Cancers
Combination dabrafenib and trametinib has demonstrated activity against multiple rare cancers harboring the BRAF V600E mutation.
Combination dabrafenib and trametinib has demonstrated activity against multiple rare cancers harboring the BRAF V600E mutation.
Anti-GPRC5D CAR T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma, a phase 2 trial suggests.
Anti-GPRC5D CAR T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma, a phase 2 trial suggests.
Though female representation on ASCO panels is increasing, women remain underrepresented on certain panels, and all-male panels still exist.
US medical oncologists may lack understanding of biosimilars and have limited access to education about these products, a survey suggests.
Using telehealth saved cancer patients an estimated $147.40 to $186.10 per visit, as well as 1.2 hours of in-clinic time and 2.9 hours of roundtrip driving time.
Combination ponatinib and blinatumomab produced durable responses in patients with newly diagnosed Ph+ acute lymphoblastic leukemia in a phase 2 trial.
Talquetamab produced responses in more than 70% of patients with relapsed/refractory multiple myeloma who received the recommended phase 2 doses.
The combination of ibrutinib and tisagenlecleucel produced durable responses in patients with relapsed/refractory mantle cell lymphoma.
Pivekimab sunirine plus azacitidine and venetoclax has demonstrated activity in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia.